Mabwell Shares Promising 7MW4811 Pre-clinical Data at 15th World ADC Conference

Mabwell (688062.SH), an innovative biopharmaceutical firm, presented the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" at the 15th World ADC San Diego conference, from November 4 to 7, 2024. The poster presentation highlighted significant data demonstrating the efficacy of 7MW4811 in treating solid tumors.

The development of 7MW4811 is based on Mabwell's cutting-edge ADC technology platform, IDDC™, which has shown promising anti-tumor activity in various solid tumors including lung, colorectal, pancreatic, and gastric cancers. The preclinical data reveals particularly encouraging therapeutic potential in gastrointestinal tumors.

The IDDC™ platform is a clinically validated site-specific conjugation technology that has greatly contributed to the development of ADCs with consistent quality, efficacy, and safety profiles. Enhanced with the novel payload Mtoxin™ (MF6), these ADCs exhibit improved pharmacodynamics, bystander killing efficacy, and capabilities to combat multidrug resistance.

Mabwell, established since 2017, is a biopharmaceutical company driven by innovation across the entire pharmaceutical industry chain. The firm aims to provide more effective and accessible therapies to meet global medical needs. Mabwell's advanced R&D system encompasses target discovery, early discovery, druggability, preclinical and clinical research, and manufacturing transformation.

Mabwell has a diverse portfolio of 15 pipeline products at various development stages, including 11 novel drug candidates and 4 biosimilars. The company's research focuses on therapeutic areas such as oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases. Among these, three products have been approved and commercialized, one has been filed for marketing authorization, and three are in pivotal trials.

Additionally, Mabwell has undertaken significant scientific and technological projects, including a national major project for "Significant New Drugs Development," two projects under National Key R&D Programmes, and several provincial and municipal innovation projects. The company’s manufacturing capabilities are robust, with its Taizhou factory meeting international GMP standards and passing the EU QP Audit.

Mabwell is currently constructing large-scale manufacturing bases in Shanghai and an ADC commercialized manufacturing base in Taizhou to further enhance its production capabilities. The company’s mission is "Explore Life, Benefit Health" with a vision of turning innovative ideas into reality, embodying their slogan, "Innovation, from ideas to reality".

For more information, please visit Mabwell's website.